Education
About Us
Working with TipRanks
Follow Us
Immucell (ICCC)
:ICCC
ICCC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.34 - $7.60
Previous CloseN/A
Volume9.49K
Average Volume (3M)33.77K
Market Cap
$62.81M
Enterprise Value$1.46B
Total Cash (Recent Filing)$4.60B
Total Debt (Recent Filing)$6.01B
Price to Earnings (P/E)―
Beta-0.26
Next Earnings
Aug 14, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.16
Shares Outstanding9,037,397
10 Day Avg. Volume17,669
30 Day Avg. Volume33,774
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio0.05
Enterprise Value/Market Cap23.30
Enterprise Value/Revenue0.18
Enterprise Value/Gross Profit0.44
Enterprise Value/Ebitda-2.41
Forecast
1Y Price Target
$8.50Price Target Upside24.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
Immucell News
PremiumCompany Announcements
ImmuCell Announces CEO Succession Planning Process
PremiumCompany Announcements
Immucell Elects Directors, Rejects Compensation ProposalsOptions Prices
Currently, No data available
---
Ownership Overview
1.58% Insiders
3.58% Mutual Funds
0.18% Other Institutional Investors
91.58% Public Companies and
Individual Investors
ICCC FAQ
What was Immucell’s price range in the past 12 months?
Immucell lowest stock price was $3.34 and its highest was $7.60 in the past 12 months.
What is Immucell’s market cap?
Immucell’s market cap is $62.81M.
When is Immucell’s upcoming earnings report date?
Immucell’s upcoming earnings report date is Aug 14, 2025 which is in 20 days.
How were Immucell’s earnings last quarter?
Immucell released its earnings results on May 14, 2025. The company reported $0.161 earnings per share for the quarter, beating the consensus estimate of N/A by $0.161.
Is Immucell overvalued?
According to Wall Street analysts Immucell’s price is currently Undervalued.
Does Immucell pay dividends?
Immucell does not currently pay dividends.
What is Immucell’s EPS estimate?
Immucell’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Immucell have?
Immucell has 9,037,397 shares outstanding.
What happened to Immucell’s price movement after its last earnings report?
Immucell reported an EPS of $0.161 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 7.943%.
Which hedge fund is a major shareholder of Immucell?
Currently, no hedge funds are holding shares in ICCC
Immucell Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.50 (24.45% Upside)
$8.50 (24.45% Upside)
Insider Transactions
Bought Shares
Worth $6.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
67.46%
12-Months-Change
Fundamentals
Return on Equity
-1.01%
Trailing 12-Months
Asset Growth
5.97%
Trailing 12-Months
Company Description
Immucell
Immucell (ICCC) is a biotechnology company operating in the animal health industry. It focuses on developing, manufacturing, and selling products that provide solutions for the prevention and treatment of diseases in livestock, primarily targeting the dairy and beef cattle markets. The company specializes in creating immune-based products that enhance animal health and productivity, with its flagship product being a first-of-its-kind USDA-licensed scours preventative for newborn calves.
ICCC Company Deck
ICCC Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong sales growth, improved gross margins, and significant adjusted EBITDA performance, driven by increased production capacity and product line expansion. However, challenges remain with FDA licensing for Re-Tain and managing backlog, alongside potential sales variability due to seasonality.Read More>